These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

203 related articles for article (PubMed ID: 31639760)

  • 1. Distinguishing Drug from Disease by Use of the Hydrashift 2/4 Daratumumab Assay.
    Thoren KL; Pianko MJ; Maakaroun Y; Landgren CO; Ramanathan LV
    J Appl Lab Med; 2019 Mar; 3(5):857-863. PubMed ID: 31639760
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isatuximab-Specific Immunofixation Electrophoresis Assay to Remove Interference in Serum M-Protein Measurement in Patients with Multiple Myeloma.
    Thoren K; Menad S; Nouadje G; Macé S
    J Appl Lab Med; 2024 Jul; 9(4):661-671. PubMed ID: 38573925
    [TBL] [Abstract][Full Text] [Related]  

  • 3. [Application of Hydrashift 2/4 daratumumab assay in eliminating interference of daratumumab on serum immunofixation electrophoresis].
    Xu S; Liu Y; Wen L; Zhao L; Deng X; Rong R; Lu J
    Zhonghua Xue Ye Xue Za Zhi; 2021 Oct; 42(10):840-845. PubMed ID: 34788924
    [No Abstract]   [Full Text] [Related]  

  • 4. Mitigating the interference of Daratumumab with immunofixation electrophoresis. A single-center experience using Hydrashift 2/4 kit.
    Duek A; Lellouche E; Ben Baruch S; Mashiach R; Segman Y; Bryk G; Leiba M
    Isr Med Assoc J; 2022 Oct; 24(10):629-633. PubMed ID: 36309856
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Use of a Daratumumab-Specific Immunofixation Assay to Assess Possible Immunotherapy Interference at a Major Cancer Center: Our Experience and Recommendations.
    Kirchhoff DC; Murata K; Thoren KL
    J Appl Lab Med; 2021 Nov; 6(6):1476-1483. PubMed ID: 34293131
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Evaluating the HYDRASHIFT 2/4 Daratumumab assay: a powerful approach to assess treatment response in multiple myeloma.
    Lee HW; Kim SM; Park HD
    Clin Chem Lab Med; 2024 Oct; 62(11):2223-2232. PubMed ID: 38630027
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Impact of M-protein detection on the response evaluations of patients undergoing treatment with the IgG-κ monoclonal antibodies daratumumab or isatuximab, and discrepancies between immunofixation electrophoresis (IFE) systems and reagents.
    Shirouchi Y; Kaihara K; Sekita T; Amano N; Nakayama K; Miyake K; Abe H; Oinuma H; Maruyama D
    Cancer Med; 2024 Aug; 13(16):e70128. PubMed ID: 39177082
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Monitoring multiple myeloma patients treated with daratumumab: teasing out monoclonal antibody interference.
    McCudden C; Axel AE; Slaets D; Dejoie T; Clemens PL; Frans S; Bald J; Plesner T; Jacobs JF; van de Donk NW; Moreau P; Schecter JM; Ahmadi T; Sasser AK
    Clin Chem Lab Med; 2016 Jun; 54(6):1095-104. PubMed ID: 27028734
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Interference of daratumumab in monitoring multiple myeloma patients using serum immunofixation electrophoresis can be abrogated using the daratumumab IFE reflex assay (DIRA).
    van de Donk NW; Otten HG; El Haddad O; Axel A; Sasser AK; Croockewit S; Jacobs JF
    Clin Chem Lab Med; 2016 Jun; 54(6):1105-9. PubMed ID: 26812873
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Monitoring the M-protein of multiple myeloma patients treated with a combination of monoclonal antibodies: the laboratory solution to eliminate interference.
    Noori S; Verkleij CPM; Zajec M; Langerhorst P; Bosman PWC; de Rijke YB; Zweegman S; VanDuijn M; Luider T; van de Donk NWCJ; Jacobs JFM
    Clin Chem Lab Med; 2021 Nov; 59(12):1963-1971. PubMed ID: 34392637
    [TBL] [Abstract][Full Text] [Related]  

  • 11. MALDI-TOF mass spectrometry distinguishes daratumumab from M-proteins.
    Moore LM; Cho S; Thoren KL
    Clin Chim Acta; 2019 May; 492():91-94. PubMed ID: 30790545
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Characteristics of isatuximab-derived interference in serum protein electrophoresis and immunofixation, and an absence of sustained in vivo interference due to belantamab mafodotin and denosumab.
    Jimenez A; Scholl AR; Wang B; Schilke M; Carlsen ED
    Clin Biochem; 2024 May; 127-128():110761. PubMed ID: 38565341
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Treatment of multiple myeloma with monoclonal antibodies and the dilemma of false positive M-spikes in peripheral blood.
    Murata K; McCash SI; Carroll B; Lesokhin AM; Hassoun H; Lendvai N; Korde NS; Mailankody S; Landau HJ; Koehne G; Chung DJ; Giralt SA; Ramanathan LV; Landgren O
    Clin Biochem; 2018 Jan; 51():66-71. PubMed ID: 27664535
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Heavy/light chain specific immunoglobulin ratios provides no additional information than serum proteins electrophoresis and immunofixation for the diagnosis and the follow-up of intact immunoglobulin multiple myeloma patients.
    Beaumont-Epinette MP; Moreau C; Besnard S; Latute F; Collet N; Sebillot M; Grosbois B; Bendavid C; Guenet L; Decaux O
    Pathol Biol (Paris); 2015 Sep; 63(4-5):215-21. PubMed ID: 26319969
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Interference of Therapeutic Monoclonal Antibodies With Routine Serum Protein Electrophoresis and Immunofixation in Patients With Myeloma: Frequency and Duration of Detection of Daratumumab and Elotuzumab.
    Tang F; Malek E; Math S; Schmotzer CL; Beck RC
    Am J Clin Pathol; 2018 Jul; 150(2):121-129. PubMed ID: 29901687
    [TBL] [Abstract][Full Text] [Related]  

  • 16. MALDI-TOF mass spectrometry can distinguish immunofixation bands of the same isotype as monoclonal or biclonal proteins.
    Fatica EM; Martinez M; Ladwig PM; Murray JD; Kohlhagen MC; Kyle RA; Kourelis T; Lust JA; Snyder MR; Dispenzieri A; Murray DL; Willrich MAV
    Clin Biochem; 2021 Nov; 97():67-73. PubMed ID: 34384797
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Electrophoretic patterns post daratumumab.
    Sheldon J; Wheeler RD; Powles R
    Ann Clin Biochem; 2018 Mar; 55(2):299-301. PubMed ID: 28490184
    [TBL] [Abstract][Full Text] [Related]  

  • 18. False positive results: a challenge for laboratory physicians and hematologists in treating multiple myeloma with daratumumab.
    Liang S; Feng W; Ma H; Zhang L; Jia C
    Hematology; 2022 Dec; 27(1):332-336. PubMed ID: 35255237
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Identifying therapeutic monoclonal antibodies using target protein collision electrophoresis reflex assay to separate the wheat from the chaff.
    Teuwen JTJ; Ritzen LFL; Knapen-Portz YM; Ludwiczek PK; Damoiseaux JGMC; van Beers JJBC; de Boer D
    J Immunol Methods; 2023 Nov; 522():113552. PubMed ID: 37652294
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Case report: serological testing interference of daratumumab (anti-CD38) therapy in multiple myeloma.
    Rabut É; Castro-Fernandez A; Le Gall V; Meknache N
    Ann Biol Clin (Paris); 2017 Jun; 75(3):351-355. PubMed ID: 28540859
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 11.